This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celebrex Warning Pains Pfizer

The Vioxx recall has shaken the once mighty Merck. The company earlier this week said that as of Oct. 31, some 475 personal injury lawsuits have been filed against the company relating to its withdrawal of Vioxx from the market on Sept. 30. Product liability cases include 1,100 plaintiff groups.

At this point, the two cases are dramatically different, but the cancer trial data are bound to renew speculation about the safety of Celebrex for treating arthritis.

In mid-October, Pfizer announced plans to fund additional clinical testing of Celebrex to determine its effect on arthritis patients who have had a recent heart attack.

Another Pfizer COX-2 inhibitor drug, Bextra, has recently drawn attention because of possible side effects, including a rare but potentially fatal skin rash, as well as some research that says Bextra patients undergoing cardiac bypass surgery had a higher risk of heart-related complications. Pfizer has released research showing that there are no increases in cardiovascular risks among patients who took Bextra for between six weeks and 52 weeks.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MRK $57.61 1.28%
PFE $35.01 -0.09%
AAPL $127.60 2.28%
FB $83.09 2.87%
GOOG $535.38 2.16%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs